Dapirolizumab pegol is under clinical development by UCB and currently in Phase III for Systemic Lupus Erythematosus. According to GlobalData, Phase III drugs for Systemic Lupus Erythematosus have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Dapirolizumab pegol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dapirolizumab pegol overview
Dapirolizumab pegol (CDP-7657) is under development for the treatment of systemic lupus erythematosus (SLE), relapsing multiple sclerosis, relapsing-remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS). The drug candidate is administered as intravenous infusion. It is a new biological entity (NBE). It is an engineered Fab fragment and polyethylene glycol conjugate. CDP-7657 is humanized anti-CD40L antibody. The drug candidate is developed based on polymer conjugate technology (PEGylation technology). It was also under development for the treatment of amyotrophic lateral sclerosis.
UCB is a biopharmaceutical company that is engaged in the discovery and development of novel medicines and solutions for the treatment of various severe diseases. It strives to develop products for the treatment of neurology and immunology related conditions. The company’s marketed products include Cimzia for ankylosing spondylitis, axial spondyloarthritis, Crohn’s disease, psoriatic arthritis, non-radiographic axial spondyloarthritis and rheumatoid arthritis; Neupro for Parkinson’s disease and restless legs syndrome; Evenity for osteoporosis, and Vimpat, Keppra and Briviact for epilepsy. The company operates through subsidiaries in the US, Japan, Germany, Italy, Spain, France, China, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Brussels-Capital Region, Belgium.
For a complete picture of Dapirolizumab pegol’s drug-specific PTSR and LoA scores, buy the report here.